Proactive Investors - Run By Investors For Investors

Medlab Clinical researching links between gut microbiome and multiple chronic diseases

Medlab Clinical Ltd (ASX:MDC) CEO & managing director Dr. Sean Hall tells Proactive Investors, "probably one of the biggest things in medicine to date" is research into the human microbiome and its impact on human health.

Modern research on the field stems from The Human Microbiome Project conducted by the US National Institute of Health starting in 2008, intended to broaden medical understanding of the role of bacteria living in and on humans.

Medlab has taken particular interest in the gut microbiome, and its connection with various chronic diseases. Research into the link with depression is the most advanced, with human patients currently being recruited for Phase IIA clinical trials of NRGBiotic™. The biotech is also researching and developing probiotic applications for the treatment and management of diabetes and chronic kidney disease.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
Meet Cardinal Resources Ltd, Legend Mining Ltd, Danakali Ltd, Predictive Discovery Ltd and Alliance Resources Ltd at our event, Melbourne , 16 July 2019. Register here »
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use